BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

223 related articles for article (PubMed ID: 25219748)

  • 1. Lupus erythematosus-like skin eruption after vemurafenib therapy.
    Reinholz M; Berking C; Hermans C; Ruzicka T; Braun-Falco M
    J Am Acad Dermatol; 2014 Oct; 71(4):e159-60. PubMed ID: 25219748
    [No Abstract]   [Full Text] [Related]  

  • 2. Cutaneous side effects of vemurafenib: a case report and discussion.
    Shea SM; Boyd K; Patterson J
    Wien Med Wochenschr; 2013 Aug; 163(15-16):376-9. PubMed ID: 23824179
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Histopathological features of cutaneous drug reactions to vemurafenib: a report of two cases.
    Dabner M; Harvey NT; Soma A; Wood BA
    Pathology; 2012 Dec; 44(7):661-4. PubMed ID: 23172086
    [No Abstract]   [Full Text] [Related]  

  • 4. Vemurafenib-induced interface dermatitis manifesting as radiation-recall and a keratosis pilaris-like eruption.
    Braunstein I; Gangadhar TC; Elenitsas R; Chu EY
    J Cutan Pathol; 2014 Jun; 41(6):539-43. PubMed ID: 24517243
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cutaneous granulomatous eruption and successful response to potent topical steroids in patients undergoing targeted BRAF inhibitor treatment for metastatic melanoma.
    Park JJ; Hawryluk EB; Tahan SR; Flaherty K; Kim CC
    JAMA Dermatol; 2014 Mar; 150(3):307-11. PubMed ID: 24352115
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Vemurafenib-induced granulomatous hepatitis.
    Spengler EK; Kleiner DE; Fontana RJ
    Hepatology; 2017 Feb; 65(2):745-748. PubMed ID: 27335285
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Vemurafenib-induced granuloma annulare.
    Lee SB; Weide B; Ugurel S; Mössner R; Enk A; Hassel JC
    J Dtsch Dermatol Ges; 2016 Mar; 14(3):305-8. PubMed ID: 26972200
    [No Abstract]   [Full Text] [Related]  

  • 8. Complete pathologic response after neoadjuvant treatment with vemurafenib for malignant melanoma.
    Kaidar-Person O; Eran A; Bar-Sela G
    J Am Acad Dermatol; 2014 Feb; 70(2):e39-41. PubMed ID: 24438978
    [No Abstract]   [Full Text] [Related]  

  • 9. Severe liver and skin toxicity after radiation and vemurafenib in metastatic melanoma.
    Anker CJ; Ribas A; Grossmann AH; Chen X; Narra KK; Akerley W; Andtbacka RH; Noyes RD; Shrieve DC; Grossmann KF
    J Clin Oncol; 2013 Jun; 31(17):e283-7. PubMed ID: 23650406
    [No Abstract]   [Full Text] [Related]  

  • 10. Multiple white cysts on face and trunk of a melanoma patient treated with vemurafenib.
    Gebhardt C; Staub J; Schmieder A; Goerdt S; Utikal J
    Acta Derm Venereol; 2015 Jan; 95(1):96-7. PubMed ID: 24710689
    [No Abstract]   [Full Text] [Related]  

  • 11. Nonmalignant cutaneous findings associated with vemurafenib use in patients with metastatic melanoma.
    Boyd KP; Vincent B; Andea A; Conry RM; Hughey LC
    J Am Acad Dermatol; 2012 Dec; 67(6):1375-9. PubMed ID: 22940405
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Unusual complication of vemurafenib treatment of metastatic melanoma: exacerbation of acantholytic dyskeratosis complicated by Kaposi varicelliform eruption.
    Gupta M; Huang V; Linette G; Cornelius L
    Arch Dermatol; 2012 Aug; 148(8):966-8. PubMed ID: 22911209
    [No Abstract]   [Full Text] [Related]  

  • 13. Four times repeated isolated limb infusion with melphalan-controlled locoregional disease in the patient with melanoma of the leg.
    El Halabi H; Hijaz F; Gushchin V
    Am Surg; 2012 Dec; 78(12):E504-5. PubMed ID: 23265100
    [No Abstract]   [Full Text] [Related]  

  • 14. Spindle cell squamous carcinoma during BRAF inhibitor therapy for advanced melanoma: an aggressive secondary neoplasm of undetermined biologic potential.
    Cohen DN; Lumbang WA; Boyd AS; Sosman JA; Zwerner JP
    JAMA Dermatol; 2014 May; 150(5):575-7. PubMed ID: 24577111
    [No Abstract]   [Full Text] [Related]  

  • 15. [Metastatic melanoma: some hope from ipilimumab and vemurafenib].
    Piérard-Franchimont C; Piérard GE
    Rev Med Liege; 2012 Feb; 67(2):64-8. PubMed ID: 22482234
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Eccrine squamous syringometaplasia associated with vemurafenib therapy.
    Story SG; Beschloss JK; Dolan CK; Thomas BC
    J Am Acad Dermatol; 2012 Nov; 67(5):e208-10. PubMed ID: 23062917
    [No Abstract]   [Full Text] [Related]  

  • 17. Induction vemurafenib followed by consolidative radiation therapy for surgically incurable melanoma.
    Seeley AR; De Los Santos JF; Conry RM
    Melanoma Res; 2015 Jun; 25(3):246-51. PubMed ID: 25746037
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Vemurafenib-induced eccrine squamous syringometaplasia.
    Lescoat A; Droitcourt C; Stock N; Le Gall F; Dupuy A
    Dermatology; 2013; 226(4):362-4. PubMed ID: 23860306
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Vemurafenib: a guide to its use in unresectable or metastatic melanoma.
    Keating GM; Lyseng-Williamson KA
    Am J Clin Dermatol; 2013 Feb; 14(1):65-9. PubMed ID: 23329082
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Hidradenitis suppurativa, eruptive melanocytic nevi, and keratosis pilaris-like eruption in a patient treated with vemurafenib.
    Ma L; Dominguez AR; Collins GR; Kia KF; Cockerell CJ
    Arch Dermatol; 2012 Dec; 148(12):1428-9. PubMed ID: 23247496
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 12.